Latest News & Updates
Sipuleucel-T (Provenge), an immunotherapy tailor-made for men with metastatic castration-resistant prostate cancer (mCRPC) using their own white blood cells, is just as potent if it is manufactured while a patient is taking enzalutamide (Xtandi), and the two drugs seem to boost immunity more effectively when administered together.
Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.
Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.
Immunotherapy is rapidly emerging as a very attractive and novel therapeutic approach for cancer, including for glioblastoma multiforme (GBM), the most common primary malignant brain tumor in adults.
It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.
Latest Peer Exchange Discussions
In this segment, the panelists discuss the use of genomic testing in conjunction with other clinical parameters for risk stratification in patients with prostate cancer. View Now
Panelists discuss the importance of education on proper side effect management with ipilimumab, particularly since experience levels with the drug tend to vary greatly in community settings. View Now
In this segment, panelists discuss several factors that contribute to the selection of a second-line treatment for patients with RAS wild-type metastatic colorectal cancer. View Now
Most Popular Right Now
Online CME Activities